Secarna Pharmaceuticals and Denali Therapeutics Enter Into Research and Option Agreement to Develop Novel Antisense Therapies in the Field of Neurodegenerative Diseases
Companies will leverage Secarna's industry-leading antisense oligonucleotide (ASO) discovery and development platform LNAplusTM and Denali's blood-brain barrier technology to discover...